PTC Therapeutics, Inc.
PTCT
Jodie situation report
PTC Therapeutics, Inc.'s current read is isolated; its market group is not confirming.
No new filing conclusion is available. 0 of 9 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 8 directly disclosed connections are confirming.
- Regulatory approvals for Upstaza/Kebildi and Sephience led to recording intangible assets and increased amortization; monitor intangible asset balances and amortization tied to these products.
Invalidation: The isolated read changes if PTCT's group or a disclosed connection begins moving with it.
Who this business touches
The relationships behind PTCT
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depends on
CLPTClearPoint Neuro Inc.supplierNov 4, 2025 ▾
“In January 2020, the Company purchased a $ 10.0 million convertible note from ClearPoint that was convertible into ClearPoint shares at a conversion rate of $ 6.00 per share at any point throughout the term of the loan, with a maturity date five years from th…”
BXBlackstone Inc.lenderFeb 19, 2026 ▾
“In October 2023, we terminated the Blackstone Credit Agreement.”
Depended on by
EWTXEdgewise Therapeutics, Inc.partnerFeb 26, 2026 ▾
“In June 2022, PTC Therapeutics presented new topline results with Translarna (ataluren), for patients with nonsense mutation Duchenne, a subset of the disease that impacts between 10% and 15% of patients.”
Filing peers
No filing peers are available for this name yet.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks 5 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
Live connections
PTCT is currently a Leader in the organic co-movement group Biotechnology. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.